We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Hunter syndrome

News List

Denali Announces Fast Track Designation to DNL310 for Hunter Syndrome americanpharmaceuticalreview
March 18, 2021
Denali Therapeutics announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ETV:IDS (DNL310) for the treatment of patients with Hunter syndrome (MPS II).
Uni of Manchester partners with AVROBIO for Hunter syndrome gene therapy pharmatimes
October 10, 2020
The University of Manchester in the UK has partnered with US-based biotech AVROBIO on the clinical development of an investigational gene therapy for mucopolysaccharidosis type II (MPS II), or Hunter syndrome.
Shire's Hunter Syndrome Treatment Failed Phase II/III Goals biospace
December 20, 2017
An experimental treatment to address cognitive impairment in pediatric patients diagnosed with the rare disease known as Hunter syndrome failed a key trial, Shire PLC announced this morning.